To compare the therapeutic efficacy of 10 mg, 40 mg, 80 mg, 160 mg and 320 mg of
albaconazole, as a single oral dose, in women affected by acute non-complicated
vulvovaginitis due to Candida spp.
A Study to Evaluate Efficacy and Safety of Three W0027 Regimens in the Treatment of Moccasin Type Tinea Pedis (MTTP)
Completed
GlaxoSmithKline
Phase 1
In this phase Ib, multi-centre, randomized, double-blind, placebo-controlled parallel group
study, 120 subjects with moccasin type tinea pedis (MTTP) will be enrolled at approximately
11 centres in the USA, Canada and Australia.
The primary objective of the study is to assess the patient response to three W0027 regimens
in subjects with MTTP. Secondary objectives include assessment of the safety, tolerability
and skin and nail pharmacokinetics to the three Albaconazole regimens.
A Study to Evaluate Efficacy and Safety of Three W0027 Regimens in the Treatment of Moccasin Type Tinea Pedis (MTTP)
Completed
Stiefel, a GSK Company
Phase 1
In this phase Ib, multi-centre, randomized, double-blind, placebo-controlled parallel group
study, 120 subjects with moccasin type tinea pedis (MTTP) will be enrolled at approximately
11 centres in the USA, Canada and Australia.
The primary objective of the study is to assess the patient response to three W0027 regimens
in subjects with MTTP. Secondary objectives include assessment of the safety, tolerability
and skin and nail pharmacokinetics to the three Albaconazole regimens.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
